These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 16012822)

  • 1. Magnetic resonance characterization of tumor microvessels in experimental breast tumors using a slow clearance blood pool contrast agent (carboxymethyldextran-A2-Gd-DOTA) with histopathological correlation.
    Preda A; Novikov V; Möglich M; Floyd E; Turetschek K; Shames DM; Roberts TP; Corot C; Carter WO; Brasch RC
    Eur Radiol; 2005 Nov; 15(11):2268-75. PubMed ID: 16012822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MRI tumor characterization using Gd-GlyMe-DOTA-perfluorooctyl-mannose-conjugate (Gadofluorine M), a protein-avid contrast agent.
    Raatschen HJ; Swain R; Shames DM; Fu Y; Boyd Z; Zierhut ML; Wendland MF; Misselwitz B; Weinmann HJ; Wolf KJ; Brasch RC
    Contrast Media Mol Imaging; 2006; 1(3):113-20. PubMed ID: 17193687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MR imaging characterization of microvessels in experimental breast tumors by using a particulate contrast agent with histopathologic correlation.
    Turetschek K; Huber S; Floyd E; Helbich T; Roberts TP; Shames DM; Tarlo KS; Wendland MF; Brasch RC
    Radiology; 2001 Feb; 218(2):562-9. PubMed ID: 11161179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carboxymethyldextran-A2-Gd-DOTA enhancement patterns in the abdomen and pelvis in an animal model.
    Daldrup-Link HE; Link TM; Möller HE; Wiedermann D; Bonnemain B; Corot C; Rummeny EJ
    Eur Radiol; 2001; 11(7):1276-84. PubMed ID: 11471624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of a rapid clearance blood pool MR contrast medium (P792) for assays of microvascular characteristics in experimental breast tumors with correlations to histopathology.
    Turetschek K; Floyd E; Shames DM; Roberts TP; Preda A; Novikov V; Corot C; Carter WO; Brasch RC
    Magn Reson Med; 2001 May; 45(5):880-6. PubMed ID: 11323815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MRI assessment of microvascular characteristics in experimental breast tumors using a new blood pool contrast agent (MS-325) with correlations to histopathology.
    Turetschek K; Floyd E; Helbich T; Roberts TP; Shames DM; Wendland MF; Carter WO; Brasch RC
    J Magn Reson Imaging; 2001 Sep; 14(3):237-42. PubMed ID: 11536400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Gadomer-17 and gadopentetate dimeglumine for differentiation of benign from malignant breast tumors with MR imaging.
    Daldrup-Link HE; Shames DM; Wendland M; Mühler A; Gossmann A; Rosenau W; Brasch RC
    Acad Radiol; 2000 Nov; 7(11):934-44. PubMed ID: 11089696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Equilibrium phase MR angiography of the aortic arch and abdominal vasculature with the blood pool contrast agent CMD-A2-Gd-DOTA in pigs.
    Kroft LJ; Doornbos J; Benderbous S; de Roos A
    J Magn Reson Imaging; 1999 Jun; 9(6):777-85. PubMed ID: 10373025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetic characterization of CMD-A2-Gd-DOTA as an intravascular contrast agent for myocardial perfusion measurement with MRI.
    Canet EP; Casali C; Desenfant A; An MY; Corot C; Obadia JF; Revel D; Janier MF
    Magn Reson Med; 2000 Mar; 43(3):403-9. PubMed ID: 10725883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media.
    Daldrup H; Shames DM; Wendland M; Okuhata Y; Link TM; Rosenau W; Lu Y; Brasch RC
    AJR Am J Roentgenol; 1998 Oct; 171(4):941-9. PubMed ID: 9762973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New macromolecular polymeric MRI contrast agents for application in the differentiation of cancer from benign soft tissues.
    Cyran CC; Fu Y; Raatschen HJ; Rogut V; Chaopathomkul B; Shames DM; Wendland MF; Yeh BM; Brasch RC
    J Magn Reson Imaging; 2008 Mar; 27(3):581-9. PubMed ID: 18219614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood pool contrast agent CMD-A2-Gd-DOTA-enhanced MR imaging of infarcted myocardium in pigs.
    Kroft LJ; Doornbos J; van der Geest RJ; de Roos A
    J Magn Reson Imaging; 1999 Aug; 10(2):170-7. PubMed ID: 10441021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor microvascular characterization using ultrasmall superparamagnetic iron oxide particles (USPIO) in an experimental breast cancer model.
    Turetschek K; Roberts TP; Floyd E; Preda A; Novikov V; Shames DM; Carter WO; Brasch RC
    J Magn Reson Imaging; 2001 Jun; 13(6):882-8. PubMed ID: 11382948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of dynamic contrast-enhanced magnetic resonance imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media.
    Daldrup H; Shames DM; Wendland M; Okuhata Y; Link TM; Rosenau W; Lu Y; Brasch RC
    Pediatr Radiol; 1998 Feb; 28(2):67-78. PubMed ID: 9472047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of Gd-DOTA in magnetic resonance imaging of experimentally induced mammary tumors.
    Bonnet PA; Michel A; Fernandez JP; Cyteval C; Rifai A; Boucard M; Chapat JP; Lamarque JL
    Magn Reson Imaging; 1990; 8(1):71-7. PubMed ID: 2325520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Slow clearance gadolinium-based extracellular and intravascular contrast media for three-dimensional MR angiography.
    Bremerich J; Colet JM; Giovenzana GB; Aime S; Scheffler K; Laurent S; Bongartz G; Muller RN
    J Magn Reson Imaging; 2001 Apr; 13(4):588-93. PubMed ID: 11276103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal functional contrast-enhanced magnetic resonance imaging: evaluation of a new rapid-clearance blood pool agent (p792) in sprague-dawley rats.
    Mandry D; Pedersen M; Odille F; Robert P; Corot C; Felblinger J; Grenier N; Claudon M
    Invest Radiol; 2005 May; 40(5):295-305. PubMed ID: 15829826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain tumor enhancement in magnetic resonance imaging at 3 tesla: intraindividual comparison of two high relaxivity macromolecular contrast media with a standard extracellular gd-chelate in a rat brain tumor model.
    Fries P; Runge VM; Bücker A; Schürholz H; Reith W; Robert P; Jackson C; Lanz T; Schneider G
    Invest Radiol; 2009 Apr; 44(4):200-6. PubMed ID: 19300099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new gadolinium-based contrast agent for magnetic resonance imaging of brain tumors: kinetic study on a C6 rat glioma model.
    Fonchy E; Lahrech H; François-Joubert A; Dupeyre R; Benderbous S; Corot C; Farion R; Rubin C; Décorps M; Rémy C
    J Magn Reson Imaging; 2001 Aug; 14(2):97-105. PubMed ID: 11477666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of iron oxide particles (AMI 227) with a gadolinium complex (Gd-DOTA) in dynamic susceptibility contrast MR imagings (FLASH and EPI) for both phantom and rat brain at 1.5 Tesla.
    Loubeyre P; De Jaegere T; Bosmans H; Miao Y; Ni Y; Landuyt W; Marchal G
    J Magn Reson Imaging; 1999 Mar; 9(3):447-53. PubMed ID: 10194716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.